DSIP, explained.
Emideltide, delta sleep-inducing peptide. Research, safety questions, and treatment context.
The form
Preparation matters
The routine
No personal schedule is set by this guide.
The evidence
See the evidence and source notes below.
Research, approval and availability are separate questions.
On this page
A linked source is not a clinical endorsement. How we handle review and corrections.
- Legal status
- Rejected by FDA advisers
FDA advisers voted 7 to 6 against allowing it on July 24, 2026.
- At Goodmorrow
- Not offered
What it is
Delta sleep-inducing peptide is a nine-amino-acid peptide first isolated in the 1970s and named for its apparent effect on deep sleep.
What the evidence shows
Human studies are old, small and inconsistent. The FDA reviewed it for opioid withdrawal, chronic insomnia and narcolepsy, and a voting member who had backed the other peptides voted against it, citing potential downstream harm.
How Goodmorrow handles it
For sleep, your clinician starts with what's driving the problem. If epitalon becomes lawful, it's the peptide we'd look at first.
Questions people ask
Why was DSIP rejected when the others passed?
The vote was 6 in favor and 7 against. One pharmacist who supported the other peptides switched, citing concern about downstream consequences.
Sources
- Secondary sourceFDA advisory panel narrowly rejects compounding of one peptide, backs two others STAT, July 24, 2026
- Secondary sourceBulk-list bound? PCAC backs majority of peptides in two-day public meeting McDermott Will & Schulte, July 28, 2026
Good days ahead.
Join the opening list for appointment updates.